China is accelerating research into vaccines and tests to cope with possible future Omicron variant outbreaks amid global concern about its potential damage.
Sino Biological, a Beijing-based company specialising in recombinant protein production, antibody development and the manufacture of test reagents, announced on Thursday it had developed a key part of the recombinant spike protein of the Omicron variant that could be used to test the efficacy of Covid-19 vaccines and antibodies.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
